

Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland 20852

> Telephone: 240-453-8120 FAX: 240-453-6909 E-mail:lisa.rooney@hhs.gov

July 17, 2008

Ronald W. Swinfard, M.D. Chief Medical Officer Lehigh Valley Hospital & Health Network Cedar Crest & I-78 PO Box 689 Allentown, PA 18104

RE: Human Research Protections Under Federalwide Assurance FWA-624

Research Project: A Randomized Comparison of Heart Rate Targeted vs. Fixed

Dose Beta Blockade in Intermediate and High Risk Patients

Undergoing Vascular Surgery

Principal Investigator: Martin Matsumura, M.D.

Dear Dr. Swinfard:

Thank you for your June 11, 2008 report in response to our May 1, 2008 letter regarding research conducted under the above-referenced research project. The information provided in the June 11, 2008 report addresses the questions and concerns outlined in the May 11, 2008 letter. As a result, there should be no need for further involvement by our office in this matter. Please notify us if you identify new information which might alter this determination.

We appreciate your institution's continued commitment to the protection of human research subjects.

Sincerely,

Lisa A. Rooney, J.D. Compliance Oversight Coordinator

cc: Dr. Scott J. Lipkin, Director, Research Participation Protection Office, and Chair, IRB

#1, Lehigh Valley Hosp & Hlth Network

Mr. Christopher Morabito, IRB Chair, Lehigh Valley Hosp & Hlth Network IRB #2

Dr. Martin Matsumura, Lehigh Valley Hospital

Page 2 of 2 Ronald W. Swinfard, M.D. - Lehigh Valley Hospital & Health Network July 17, 2008

Dr. Andrew C. von Eschenbach, Commissioner, FDA Dr. Joanne R. Less, FDA